Clindamycin in the treatment of osteomyelitis in children: a report of 29 cases
W. Rodriguez, S. Ross, W. Khan, D. McKay and P. Moskowitz
Clindamycin phosphate was used in the treatment of 29 children with
osteomyelitis of whom 25 had an acute and four a chronic type of infection.
The usual dose was 50 mg/kg/day intravenously for approximately three weeks
followed by oral clindamycin palmitate at home in a dose of 30 mg/kg/day
for an additional six weeks. Staphylococcus aureus was isolated in 22 of 29
cases: 96% of strains were penicillin resistant. The clinical and
bacteriologic results in the present series were good to excellent. There
was prompt clinical and bacteriologic response shortly after initiation of
clindamycin therapy. Good bone penetration of the drug was observed.
Long-term evaluation revealed satisfactory clinical and roentgenographic
progress in all patients. No diarrhea or manifestations of enterocolitis
appeared in any patient in spite of high doses of the drug for intervals up
to nine weeks.
